Natriuretic peptides in diagnosis of pulmonary hypertension


Cite item

Full Text

Abstract

Pathogenetic and diagnostic role of natriuretic peptides in different variants of pulmonary hypertension is discussed. Structure, mechanism of action and physiological effects of some natriuretic peptides and their role in diagnosis and monitoring of the course of pulmonary hypertension are described.

References

  1. Rubin L. J. Pulmonary arterial hypertension. Proc. Am. Thorac. Soc. 2006; 3: 111-115.
  2. Мухарлямов Н. М. Легочная гипертония. Легочное сердце. В кн. Чазов Е. И. (ред.). Болезни сердца и сосудов. М.; 1992; 3: 230-279.
  3. Задионченко В. С., Погонченкова И. В., Гринева З. О. и др. Хроническое легочное сердце. Рос. кардиол. журн. 2003; 4: 5-10.
  4. Rich S., Dantzker D. R., Ayres S. M. et al. Primary pulmonary hypertension: a national prospective study. Ann. Intern. Med. 1987; 107: 216-223.
  5. The Task Force on Diagnosis and Treatment of Pulmonary Arterial Hypertension of the European Society of Cardiology. Guidelines on diagnosis and treatment of pulmonary arterial hypertension. Eur. Heart J. 2004; 25: 2243-2278.
  6. Arcasoy S., Christie J., Ferrari V. et al. Echocardiographic assessment of pulmonary hypertension in patients with advanced lung disease. Am. J. Respir. Crit. Care Med. 2003; 167: 735- 740.
  7. Мартынюк Т. В., Амбатьелло Л. Г., Наконечников С. Н., Чазова И. Е. Диагностика легочной артериальной гипертензии. Тер. арх. 2008; 4: 33-38.
  8. Kirsch В. Electron microscopy of the atrium of the heart. Exp. Med. Surg. 1956; 14: 99-111.
  9. de Bold A. J., Borenstein H. B., Veress A. T. et al. A rapid and potent natriuretic response to intravenous injection of atrial myocardial extract in rats. Life Sci. 1981; 8: 89-94.
  10. Currie M. G., Geller D. M., Cole B. R. et al. Bioactive cardiac substances: potent vasorelaxant activity in mammalian atria. Science 1983; 221: 71-73.
  11. Flynn T. G., de Bold M. L., de Bold A. J. The amino acid sequence of an atrial peptide with potent diuretic and natriuretic properties. Biochem. Biophys. Res. Commun. 1983; 117: 859-865.
  12. Sudoh Т., Kangawa K., Minamino N., Matsuo H. A new natriuretic peptide in porcine brain. Nature 1988; 332: 78-81.
  13. Schulz-Knappe P., Forssmann K., Herbst F. et al. Isolation and structural analysis of "urodilatin", a new peptide of the cardiodilatin-(ANP)-family, extracted from human urine. Klin. Wschr. 1988; 66: 752-759.
  14. Levin E. R., Gardner D. G., Samson W. K. Natriuretic peptides. N. Engl. J. Med. 1998; 339: 321-328.
  15. Yasue H., Yoshimura M., Sumida H. et al. Localization and mechanism of secretion of B-type natriuretic peptide in comparison with those of A-type natriuretic peptide in normal subjects and patients with heart failure. Circulation 1994; 90: 195- 203.
  16. Soeki Т., Kishimoto I., Okumura H. et al. C-type natriuretic peptide, a novel antifibrotic and antihypertrophic agent, prevents cardiac remodeling after myocardial infarction. J. Am. Coll. Cardiol. 2005; 45: 608-616.
  17. Schirger J. A., Heublein D. M., Chen H. H. et al. Presence of Dendroaspis natriuretic peptide-like immunoreactivity in human plasma and its increase during human heart failure. Mayo Clin. Proc. 1999; 74: 126-130.
  18. Chinkers M., Garbers D. L., Chang M. S. et al. A membrane form of guanylate cyclase is an atrial natriuretic peptide receptor. Nature 1989; 338: 78-83.
  19. Oliver P. M., Fox J. E., Kim R. et al. Hypertension, cardiac hypertrophy, and sudden death in mice lacking natriuretic peptide receptor A. Proc. Natl. Acad. Sci. USA 1997; 94: 14730-14735.
  20. Anand-Srivastava M. B. Natriuretic peptide receptor-C signaling and regulation. Peptides 2005; 26: 1044-1059.
  21. Roques B. P. Cell surface metallopeptidases involved in blood pressure regulation: structure, inhibition and clinical perspectives. Pathol. Biol. (Paris) 1998; 46: 191-200.
  22. Imura H., Nakao K., Itoh H. The natriuretic peptide system in the brain: implications in the central control of cardiovascular and neuroendocrine functions. Front. Neuroendocrinol. 1992; 13: 217-249.
  23. Елисеев О. М. Натрийуретические пептиды. Эволюция знаний. Тер. арх. 2003; 9: 40-45.
  24. Butt E., Bernhardt M., Smolenski A. et al. Endothelial nitric-oxide synthase (type III) is activated and becomes calcium independent upon phosphorylation by cyclic nucleotide-dependent protein kinases. J. Biol. Chem. 2000; 275: 5179-5187.
  25. Rybalkin S. D., Rybalkina I. G., Feil R. et al. Regulation of cGMP-specific phosphodiesterase (PDE5) phosphorylation in smooth muscle cells. J. Biol. Chem. 2002; 277: 3310-3317.
  26. Wijeyaratne C. N., Moult P. J. The effect of alpha human atrial natriuretic peptide on plasma volume and vascular permeability in normotensive subjects. J. Clin. Endocrinol. 1993; 76: 343-346.
  27. Yamahara K., Itoh H., Chun Т. Н. et al. Significance and therapeutic potential of the natriuretic peptides/cGMP/cGMP-dependent protein kinase pathway in vascular regeneration. Proc. Natl. Acad. Sci. USA 2003; 100: 3404-3409.
  28. Chauhan S. D., Nilsson H., Ahluwalia A., Hobbs A. J. Release of C-type natriuretic peptide accounts for the biological activity of endothelium-derived hyperpolarizing factor. Proc. Natl. Acad. Sci. USA 2003; 100: 1426-1431.
  29. Lainchbury J. G., Lisy O., Burnett J. C. J. et al. Actions of a novel synthetic natriuretic peptide on hemodynamics and ventricular function in the dog. Am. J. Physiol. Reg. Integrat. Comp. Physiol. 2002; 282: R993-R998.
  30. Mueller Т., Gegenhuber A., Poelz W., Haltmayer M. Head-to-head comparison of the diagnostic utility of BNP and NT-proBNP in symptomatic and asymptomatic structural heart disease. Clin. Chim. Acta 2004; 341: 41-48.
  31. Bando M., Ishii Y., Sugiyama Y., Kitamura S. Elevated plasma brain natriuretic peptide levels in chronic respiratory failure with cor pulmonale. Respir. Med. 1999; 93: 507-514.
  32. Gan С. Т., McCann G. P., Marcus J. T. et al. NT-proBNP reflects right ventricular structure and function in pulmonary hypertension. Eur. Respir. J. 2006; 28: 1190-1194.
  33. Nagaya N., Nishikimi Т., Uematsu M. et al. Plasma brain natriuretic peptide as a prognostic indicator in patients with primary pulmonary hypertension. Circulation 2000; 102: 865-870.
  34. Wiedemann R., Ghofrani H. A., Weissmann N. et al. Atrial natriuretic peptide in severe primary and nonprimary pulmonary hypertension: response to iloprost inhalation. J. Am. Coll. Cardiol. 2001; 38: 1130-1136.
  35. Leuchte H. H., Holzapfel M., Baumgartner R. A. et al. Clinical significance of brain natriuretic peptide in primary pulmonary hypertension. J. Am. Coll. Cardiol. 2004; 43: 764-770.
  36. Leuchte H. H., Holzapfel M., Baumgartner R. A. et al. Characterization of brain natriuretic peptide in long-term follow-up of pulmonary arterial hypertension. Chest 2005; 128: 2368-2374.
  37. Suntharalingam J., Goldsmith K., Toshner M. et al. Role of NT-proBNP and 6MWD in chronic thromboembolic pulmonary hypertension. Respir. Med. 2007; 101 (11): 2254-2262.
  38. Nagaya N., Nishikimi T., Uematsu M. et al. Secretion patterns of brain natriuretic peptide and atrial natriuretic peptide in patients with or without pulmonary hypertension complicating atrial septal defect. Am. Heart J. 1998; 136: 297-301.
  39. Leuchte H. H., Baumgartner R. A., Nounou M. E. et al. Brain natriuretic peptide is a prognostic parameter in chronic lung disease. Am. J. Respir. Crit. Care Med. 2006; 173: 744-750.
  40. Bozkanat E., Tozkoparan E., Baysan O. et al. The significance of elevated brain natriuretic peptide levels in chronic obstructive pulmonary disease. J. Intern. Med. Res. 2005; 33: 537- 544.
  41. Stolz D., Breidthardt T., Christ-Crain M. et al. Use of B-type natriuretic peptide in the risk stratification of acute exacerbations of COPD. Chest 2008; 133 (5): 1088-1094.
  42. Ishii J., Nomura M., Ito M. et al. Plasma concentration of brain natriuretic peptide as a biochemical marker for the evaluation of right ventricular overload and mortality in chronic respiratory disease. Clin. Chim. Acta 2000; 301: 19-30.
  43. Wilkins M. R., Paul G. A., Strange J. W. et al. Sildenafil versus Endothelin Receptor Antagonist for Pulmonary Hypertension (SERAPH) study. Am. J. Respir. Crit. Care Med. 2005; 171: 1292-1297.
  44. Andreassen A. K., Wergeland R., Simonsen S. et al. N-terminal pro-B-type natriuretic peptide as an indicator of disease severity in a heterogeneous group of patients with chronic precapillary pulmonary hypertension. Am. J. Cardiol. 2006; 98: 525- 529.
  45. Fijalkowska A., Kurzyna M., Torbicki A. et al. Serum N-terminal brain natriuretic peptide as a prognostic parameter in patients with pulmonary hypertension. Chest 2006; 129: 1313- 1321.
  46. Souza R., Bogossian H. B., Humbert M. et al. N-terminal pro-brain natriuretic peptide as a haemodynamic marker in idiopathic pulmonary arterial hypertension. Eur. Respir. J. 2005; 25: 509-513.
  47. Souza R., Jardim C., Julio Cesar Fernandes C. et al. NT-proBNP as a tool to stratify disease severity in pulmonary arterial hypertension. Respir. Med. 2007; 101: 69-75.
  48. Allanore Y., Borderie D., Meune C. et al. N-terminal pro-brain natriuretic peptide as a diagnostic marker of early pulmonary artery hypertension in patients with systemic sclerosis and effects of calcium-channel blockers. Arthr. and Rheum. 2003; 48: 3503-3508.
  49. Williams M. H., Handler C. E., Akram R. et al. Role of N-terminal brain natriuretic peptide (NT-proBNP) in scleroderma-associated pulmonary arterial hypertension. Eur. Heart J. 2006; 27: 1485-1494.
  50. Leuchte H. H., Neurohr C., Baumgartner R. et al. Brain natriuretic peptide and exercise capacity in lung fibrosis and pulmonary hypertension. Am. J. Respir. Crit. Care Med. 2004; 170: 360-365.
  51. Allanore Y., Borderie D., Avouac J. et al. High N-terminal pro-brain natriuretic peptide levels and low diffusing capacity for carbon monoxide as independent predictors of the occurrence of precapillary pulmonary arterial hypertension in patients with systemic sclerosis. Arthr. and Rheum. 2008; 58 (1): 284-291.
  52. Мухин Н. А., Попова Е. Н., Коган Е. А. и др. Клиническое значение ремоделирования легочного сосудистого русла при идиопатическом фиброзирующем альвеолите. Сердеч. недостат. 2007; 8 (4): 178-181.
  53. Galie N., Olschewski H., Oudiz R. J. et al. Ambrisentan for the treatment of pulmonary arterial hypertension: results of the ambrisentan in pulmonary arterial hypertension, randomized, double-blind, placebo-controlled, multicenter, efficacy (ARIES) study 1 and 2. Circulation 2008; 117 (23): 3010-3019.
  54. Мартынюк Т. В., Масенко В. П., Чазова И. Е., Беленков Ю. Н. Эндотелиальная дисфункция у больных с легочной гипертензией. Кардиология 1997; 37 (10): 25-29.
  55. Чазова И. Е., Мартынюк Т. В., Масенко В. П. и др. Роль легких в метаболизме некоторых маркеров повреждения эндотелия в норме и при первичной легочной гипертензии. Кардиология 2000; 40 (8): 13-15.
  56. Emori Т., Hirata Y., Imai Т. et al. Cellular mechanism of natriuretic peptides-induced inhibition of endothelin-1 biosynthesis in rat endothelial cells. Endocrinology 1993; 133 (6): 2474-2480.
  57. Mitani Y., Maruyama J., Jiang B. H. et al. Atrial natriuretic peptide gene transfection with a novel envelope vector system ameliorates pulmonary hypertension in rats. J. Thorac. Cardiovasc. Surg. 2008; 136 (1): 142-149.
  58. Makino N., Sugano M., Satoh S. et al. Peroxisome proliferator-activated receptor-gamma ligands attenuate brain natriuretic peptide production and affect remodeling in cardiac fibroblasts in reoxygenation after hypoxia. Cell Biochem. Biophys. 2006; 44 (1): 65-71.
  59. Kim S. Z., Cho K. W., Kim S. H. et al. Modulation of endocardial natriuretic peptide receptors in right ventricular hypertrophy. Am. J. Physiol. 1999; 277 (6, pt 2): H2280-H2289.
  60. Munagala V. K., Burnett J. C. Jr., Redfield M. M. The natriuretic peptides in cardiovascular medicine. Curr. Probl. Cardiol. 2004; 29: 707-769.
  61. Leuchte H. H., El Nounou M., Tuerpe J. C. et al. N-Terminal pro-brain natriuretic peptide and renal insufficiency as predictors of mortality in pulmonary hypertension. Chest 2007; 131: 402-409.
  62. Warwick G., Thomas P. S., Yates D. H. Biomarkers in pulmonary hypertension. Eur. Respir. J. 2008; 32: 503-512.
  63. Vizza C. D., Letizia C., Petramala L. et al. Venous endotelin-1 (ET-1) and brain natriuretic peptide (BNP) plasma levels during 6-month bosentan treatment for pulmonary arterial hypertension. Regul. Pept. 2008; 151 (1-3): 48-53.

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

Copyright (c) 2009 Consilium Medicum

Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
 

Address of the Editorial Office:

  • Novij Zykovskij proezd, 3, 40, Moscow, 125167

Correspondence address:

  • Alabyan Street, 13/1, Moscow, 127055, Russian Federation

Managing Editor:

  • Tel.: +7 (926) 905-41-26
  • E-mail: e.gorbacheva@ter-arkhiv.ru

 

 © 2018-2021 "Consilium Medicum" Publishing house


This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies